Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Population and treatments', 'Unit costs', 'Capacity', 'Adverse events' and 'Payscales' worksheets in the template to reflect local data and assumptions.
Guidance recommendation
Financial and capacity resource impact
The key drivers of resource impact are that:
-
The treatment duration of tisotumab vedotin is longer than that of comparator treatments.
-
The number of administrations per cycle of tisotumab vedotin is fewer than that of comparator treatments.
-
The number of ophthalmology appointments for people having tisotumab vedotin is greater than that for comparator treatments.
-
The price of tisotumab vedotin is different than that of comparator treatments.
The company has a commercial arrangement. This makes tisotumab vedotin available to the NHS at a discount.
Users can input the confidential price of tisotumab vedotin and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on whether the technology is classified as high cost.
Table 1 shows the impact on capacity activity in each of the next 3 years.
| Year | Number of administration appointments | Number of ophthalmology appointments |
|---|---|---|
|
Current practice (without tisotumab vedotin) |
3,260 |
0 |
|
Year 1 |
2,840 |
550 |
|
Year 2 |
2,630 |
830 |
|
Year 3 |
2,410 |
1,110 |
For further analysis or to calculate the financial and capacity impact, see the resource impact template.
Eligible population for tisotumab vedotin
Table 2 shows the population who are eligible for tisotumab vedotin and the number of people who are expected to have tisotumab vedotin in each of the next 3 years, excluding forecast population growth.
| Eligible population and uptake | Number of people eligible for tisotumab vedotin | Uptake for tisotumab vedotin (%) | Number of people having tisotumab vedotin each year |
|---|---|---|---|
|
Current practice without tisotumab vedotin |
280 |
0 |
0 |
|
Year 1 |
280 |
30 |
80 |
|
Year 2 |
280 |
45 |
120 |
|
Year 3 |
280 |
60 |
170 |
The following assumptions have been used to calculate the eligible population:
-
There are around 2,400 new cervical diagnoses each year in England.
-
25.76% of diagnoses are at stages 3 or 4.
-
67% have first-line treatment.
-
67% of people who have first-line treatment have second-line treatment.
The uptake for tisotumab vedotin is based on information received from NHS England.
Treatment options for the eligible population
The alternative treatment options for the eligible population are gemcitabine and paclitaxel. All 3 drugs are administered by intravenous infusion. But tisotumab vedotin is administered in a single infusion per cycle while paclitaxel is given on days 1, 8 and 15 of a 21‑day cycle and gemcitabine is given on days 1 and 8. Other regimens such as topotecan may be used locally but are not included in the resource impact template.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
02H, Cancer, Urological |
| Commissioner |
NHS England |
| Provider |
NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment and should be read with it.
ISBN: 978-1-4731-9559-2
This page was last updated: